Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic SyndromeGarrett W. Rhyasen, Daniel T. Starczynowski, Noel Southall et al.|Cancer Cell|2013Cited by 203
Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1Jing Fang, Daniel T. Starczynowski, Garrett W. Rhyasen et al.|Blood|2012Cited by 103
A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromesJing Fang, Daniel T. Starczynowski, Xiaona Liu et al.|Nature Medicine|2016Cited by 83
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II studyEsther Natalie Olíva, Roberto Latagliata, Maria Cuzzola et al.|Annals of Hematology|2012Cited by 27